Evidence map›Paper›PMID 26621909›Full record

Trial reportThe Journal of infectious diseases2016

Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings.

Rupak Shivakoti, Wei-Teng Yang, Sima Berendes, Noluthando Mwelase, Cecilia Kanyama, Sandy Pillay, Wadzanai Samaneka, Breno Santos, Selvamuthu Poongulali, Srikanth Tripathy and 11 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Association of serum vitamin BJournal of family medicine and primary care · 2022
    Article
  11. Article
  12. Article
  13. Acute phase protein response to viral infection and vaccination.Archives of biochemistry and biophysics · 2019
    Review
  14. Article
  15. Intestinal Barrier Dysfunction and Microbial Translocation in Human Immunodeficiency Virus-Infected Pregnant Women Are Associated With Preterm Birth.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 8 countries.

Rupak ShivakotiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Wei-Teng YangDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sima BerendesMalawi College of Medicine-Johns Hopkins University Research Project, Blantyre.
Noluthando MwelaseDepartment of Medicine, University of Witwatersrand, Johannesburg.
Cecilia KanyamaUNC Project-Malawi, Lilongwe, Malawi.
Sandy PillayDurban International Clinical Research Site, Durban University of Technology, South Africa.
Wadzanai SamanekaUniversity of Zimbabwe Clinical Research Centre, Harare.
Breno SantosHospital Nossa Senhora de Conceição, Porto Alegre.
Selvamuthu PoongulaliYR Gaitonde Center for AIDS Research and Education, Chennai.
Srikanth TripathyNational AIDS Research Institute, Pune, India.
Cynthia RiviereLes Centres GHESKIO, Port-Au-Prince, Haiti.
Javier R LamaAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Sandra W CardosoSTD/AIDS Clinical Research Laboratory, Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Patcharaphan SugandhavesaResearch Institute for Health Sciences, Chiang Mai, Thailand.
Ashwin BalagopalDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nikhil GupteDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Richard D SembaDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Thomas B CampbellDivision of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora.
Robert C BollingerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Amita GuptaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
NWCS 319 and PEARLS Study Team
Johns Hopkins University · USJohns Hopkins Medicine · USAsociación Civil Impacta Salud y Educación · PEDurban University of Technology · ZAFundação Oswaldo Cruz · BRGheskio Centers · HTHospital Nossa Senhora da Conceição · BRNational AIDS Research Institute · INUniversity of Colorado Denver · USUniversity of Malawi · MWUniversity of the Witwatersrand · ZAUniversity of Zimbabwe · ZWYR Gaitonde Centre for AIDS Research and Education · IN

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
The Progression of Hepatitis C Among IDUs with HIVR01DA016078 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BALAGOPAL, ASHWIN, THOMAS, DAVID L · 2002 to 2016
$10.9M
Impact of Malnutrition on HIV Treatment Failure in Resource-Limited SettingsR01AI080417 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GUPTA, AMITA · 2009 to 2012
$2.3M
NIAID NIH HHS R01 AI080417NIAID NIH HHS R01AI080417NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1AI068636NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1AI069465NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1AI106701
6 · The paper itself

Abstract

A case-cohort analysis of human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART) was performed within a multicountry randomized trial (PEARLS) to assess the prevalence of persistently elevated C-reactive protein (CRP) levels, based on serial measurements of CRP levels, and their association with HIV clinical failure. A persistently elevated CRP level in plasma (defined as ≥ 5 mg/L at both baseline and 24 weeks after ART initiation) was observed in 50 of 205 individuals (24%). A persistently elevated CRP level but not an elevated CRP level only at a single time point was independently associated with increased clinical failure, compared with a persistently low CRP level, despite achievement of virologic suppression. Serial monitoring of CRP levels could identify individuals who are at highest risk of HIV progression and may benefit from future adjunct antiinflammatory therapies.

Indexed as

AdultAnti-HIV AgentsCase-Control StudiesC-Reactive ProteinFemaleGlobal HealthHIV InfectionsHumansInflammationMaleTreatment FailureAnti-HIV AgentsC-Reactive Proteinantiretroviral therapyCRPHIVinflammationpersistent inflammation

Identifiers

PMID26621909
PMCPMC4779305
OpenAlexW2226535973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.